These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7940560)

  • 21. Assessment of potential aluminum chelators in an octanol/aqueous system and in the aluminum-loaded rabbit.
    Yokel RA; Kostenbauder HB
    Toxicol Appl Pharmacol; 1987 Nov; 91(2):281-94. PubMed ID: 3672527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aluminum toxicokinetics in peritoneal dialysis patients.
    Yue CS; Christie M; Lavergne V; Sikaneta T; Taskapan H; Mardini K; Tam P; Ting R; Ghannoum M
    Clin Toxicol (Phila); 2011 Aug; 49(7):659-63. PubMed ID: 21819285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.
    Singh S; Epemolu RO; Dobbin PS; Tilbrook GS; Ellis BL; Damani LA; Hider RC
    Drug Metab Dispos; 1992; 20(2):256-61. PubMed ID: 1352218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative aluminium mobilizing actions of several chelators in aluminium-loaded uraemic rats.
    Gómez M; Domingo JL; del Castillo D; Llobet JM; Corbella J
    Hum Exp Toxicol; 1994 Feb; 13(2):135-9. PubMed ID: 7908811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined chelation of bi-functional bis-hydroxypiridinone and mono-hydroxypiridinone: synthesis, solution and in vivo evaluation.
    Gama S; Gil M; Gano L; Farkas E; Amélia Santos M
    J Inorg Biochem; 2009 Feb; 103(2):288-98. PubMed ID: 19091421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lethality, accumulation and toxicokinetics of aluminum in some tissues of male albino rats.
    Rawy SM; Morsy GM; Elshibani MM
    Toxicol Ind Health; 2013 Apr; 29(3):254-63. PubMed ID: 22317823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetics of aluminum disposition after ingestion of low to moderate pharmacological doses of aluminum.
    Sutherland JE; Greger JL
    Toxicology; 1998 Mar; 126(2):115-25. PubMed ID: 9620543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An aluminum-induced increase in GFAP is attenuated by some chelators.
    Yokel RA; O'Callaghan JP
    Neurotoxicol Teratol; 1998; 20(1):55-60. PubMed ID: 9511169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
    Yokel RA
    J Toxicol Environ Health; 1994 Feb; 41(2):131-74. PubMed ID: 8301696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bile is an important route of elimination of ingested aluminum by conscious male Sprague-Dawley rats.
    Sutherland JE; Radzanowski GM; Greger JL
    Toxicology; 1996 May; 109(2-3):101-9. PubMed ID: 8658541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo comparative studies on chelation of aluminum by some polyaminocarboxylic acids.
    Graff L; Muller G; Burnel D
    Res Commun Mol Pathol Pharmacol; 1995 Jun; 88(3):271-92. PubMed ID: 8564384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic and pharmacokinetic evaluation of a novel 3-hydroxypyridinone iron chelator, CP502, in the rat.
    Novakovic J; Tesoro A; Thiessen JJ; Spino M
    Eur J Drug Metab Pharmacokinet; 2004; 29(4):221-4. PubMed ID: 15726881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entry, half-life, and desferrioxamine-accelerated clearance of brain aluminum after a single (26)Al exposure.
    Yokel RA; Rhineheimer SS; Sharma P; Elmore D; McNamara PJ
    Toxicol Sci; 2001 Nov; 64(1):77-82. PubMed ID: 11606803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Al-toxicity studies in yeast using gallium as an aluminum analogue.
    Ritchie RJ; Raghupathi SS
    Biometals; 2008 Aug; 21(4):379-93. PubMed ID: 18058193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ
    Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chelation of aluminum by combining deferasirox and deferiprone in rats.
    Saljooghi AS
    Toxicol Ind Health; 2012 Sep; 28(8):740-5. PubMed ID: 22025507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New hydroxypyridinone-functionalized sepharoses as sorbing agents for hard metal ions.
    Grazina R; Santos MA
    J Hazard Mater; 2011 Feb; 186(2-3):1902-8. PubMed ID: 21239106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease.
    Shin RW; Kruck TP; Murayama H; Kitamoto T
    Brain Res; 2003 Jan; 961(1):139-46. PubMed ID: 12535786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.
    Porter JB; Singh S; Hoyes KP; Epemolu O; Abeysinghe RD; Hider RC
    Adv Exp Med Biol; 1994; 356():361-70. PubMed ID: 7887242
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.